# A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment

> **NCT05497297** · PHASE1 · COMPLETED · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 42 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** HSK7653 tablets

## Key facts

- **NCT ID:** NCT05497297
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-04
- **Primary completion:** 2022-10-23
- **Final completion:** 2022-10-26
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2023-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05497297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05497297, "A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal Impairment". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05497297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*